Adverse effects of depolarising neuromuscular blocking agents. Incidence, prevention and management.
Muscle relaxants block neuromuscular transmission, acting at nicotinic acetylcholine receptors of the neuromuscular junction. Suxamethonium (succinylcholine) is a depolarising agent, whereas all other relaxants in clinical use are nondepolarising. The desired neuromuscular block results from the structural similarity of muscle relaxants to acetylcholine, enabling the interaction with receptors at the neuromuscular junction. Adverse effects of suxamethonium are generally related to its agonist mode of action. Autonomic cardiovascular effects may result. Other adverse effects include anaphylactic or anaphylactoid reactions, and histamine release. Various disease states may present specific considerations in the use of muscle relaxants. Although many complications of muscle relaxants (such as prolonged block or resistance) are easily treated, others may require immediate intervention and vigorous therapy. Careful selection of appropriate relaxants for particular patients will usually prevent the occurrence of complications.
Department of Anesthesiology, Mount Sinai Medical Center, New York, New York.
W J
WJ
Book
M
M
Abel
J B
JB
Eisenkraft
D001145:Arrhythmias, Cardiac / Q000139:chemically induced; D004348:Drug Labeling; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects; D008305:Malignant Hyperthermia / Q000378:metabolism / Q000628:therapy; D009467:Neuromuscular Depolarizing Agents / Q000009:adverse effects*; D009469:Neuromuscular Junction / Q000187:drug effects*; D012206:Rhabdomyolysis / Q000378:metabolism / Q000628:therapy; D013035:Spasm / Q000139:chemically induced; D013390:Succinylcholine / Q000009:adverse effects*
D009467:Neuromuscular Depolarizing Agents; D013390:Succinylcholine